Welcome to our dedicated page for PYXUS INTERNATIONAL SEC filings (Ticker: PYYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PYXUS INTERNATIONAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PYXUS INTERNATIONAL's regulatory disclosures and financial reporting.
PYXUS INTERNATIONAL, INC. officer Joshua David Erdei, Chief Human Resources Officer, reports his equity interests. These include restricted stock units representing 18,000 shares of common stock that were fully earned for vesting through March 31, 2024, subject to a future Vesting Event, and a separate award of restricted stock units covering 15,600 underlying common shares, part of which is fully earned and part to be earned through March 31, 2027. Each unit represents a contingent right to receive one share of common stock. Erdei also reports 72 common shares held indirectly through his spouse’s IRA and disclaims beneficial ownership of those securities.
Pyxus International, Inc. reports the results of its 2026 annual meeting of shareholders held on August 13, 2026. Shareholders elected seven directors—John S. Alphin, Jamie J. Ashton, Patrick J. Bartels, Jr., Robert D. George, Cynthia P. Moehring, J. Pieter Sikkel and Richard J.C. Topping—for one-year terms expiring at the 2027 annual meeting.
Shareholders also ratified the appointment of Deloitte & Touche LLP as independent auditors for the fiscal year ending March 31, 2027, with 20,237,672 votes for and 635 against. In addition, shareholders approved, on an advisory basis, the compensation of the company’s named executive officers, receiving 18,392,358 votes for, 748,737 against and 830 abstentions, with 1,096,382 broker non-votes.
Pyxus International reported first quarter fiscal 2027 results for the period ended June 30, 2026. Sales and other operating revenues were $437.8 million, down from $508.8 million a year earlier, mainly from lower average tobacco prices and shipment timing, particularly in North America.
Gross profit was $61.4 million with a margin of 14.0%, up from 12.9% as regional mix, especially Europe, supported pricing. Operating income was $15.7 million. Net loss attributable to Pyxus narrowed to $7.3 million from $15.8 million, helped by a $5.7 million income tax benefit versus a prior-year tax expense.
Adjusted EBITDA was $27.7 million compared with $29.5 million. Leaf tobacco inventories declined to $1,065.2 million and net debt decreased by $130.9 million to $1,108.7 million, with $175.9 million of cash and no borrowings on the $150.0 million ABL facility. The company maintained full‑year fiscal 2027 guidance for net sales of $2.3–$2.5 billion and Adjusted EBITDA of $210–$240 million.
Pyxus International, Inc. reported fiscal first‑quarter 2027 results for the three months ended June 30, 2026. Sales and other operating revenues were $437.8 million, down 14.0% from $508.8 million, mainly from lower leaf tobacco prices in South America and Africa and shipment timing in North America. Gross profit was $61.4 million versus $65.6 million, with margin improving to 14.0% from 12.9%. Operating income was $15.7 million, and the net loss attributable to Pyxus narrowed to $7.3 million, or $0.28 per share, from a $15.8 million loss, helped by a $5.7 million income tax benefit and higher income from unconsolidated affiliates.
Unprocessed tobacco inventories were $393.5 million and processed tobacco $671.6 million; management notes total tobacco inventories declined $24.6 million, or 2.3%, year over year, with higher carry‑over processed volumes and slower green purchases. Debt totaled $1,284.6 million and cash and equivalents $175.9 million, resulting in net debt of $1,108.7 million. Net cash used in operating activities was $359.7 million, reflecting seasonal working‑capital build, funded largely by $353.6 million of net short‑term borrowings and $58.5 million of collections from securitized receivables. Management highlights elevated Southern Hemisphere crop production, higher uncommitted processed inventory of $60.3 million, reliance on foreign seasonal lines of credit with $351.4 million remaining available, and potential weather impacts from a forecast “Super” El Niño as key considerations.
Pyxus International is asking shareholders to elect seven directors, ratify Deloitte & Touche LLP as independent auditors for the year ending March 31, 2027, and approve on an advisory basis the compensation of its named executive officers.
The proxy details governance structures, large shareholders and executive pay. There were 24,607,791 common shares outstanding as of June 12, 2026, all held in street name. CEO J. Pieter Sikkel received total 2026 compensation of $1.8 million, including base salary, annual incentive and a discretionary bonus, with bonuses tied to Adjusted EBITDA and Corporate Operational EBITDA performance goals.
Pyxus International reported strong fourth-quarter and solid full-year 2026 results, highlighted by record profitability and improved leverage. Q4 sales rose 35.2% year-over-year to $678.2 million, driven by higher leaf sales volumes from Africa and North America, lifting gross profit to $94.4 million and operating income to $43.7 million.
For the year ended March 31, 2026, sales slipped 2.8% to $2.413 billion as lower average pricing offset volume gains, but gross profit improved to $347.7 million and operating income increased to $162.7 million. Net income attributable to Pyxus was $14.6 million, or $0.56 per diluted share, and adjusted EBITDA reached a record $226.7 million.
Liquidity and balance sheet metrics strengthened: Q4 operating cash flow was $310.1 million, adjusted free cash flow was $352.1 million, cash and cash equivalents increased to $134.3 million, and net debt/adjusted EBITDA improved to 3.52x. For fiscal 2027, the company guides to $2.3–$2.5 billion of sales and $210–$240 million of adjusted EBITDA.
Pyxus International files its annual report showing $2,413.0 million in tobacco sales for the year ended March 31, 2026. The global leaf business remains the core, with Africa, Asia, Europe and other regions all contributing meaningfully.
The company carries $932.9 million of indebtedness and relies heavily on short- and long-term credit facilities, with $747.3 million available for borrowing at year-end. Tobacco inventories were $786.7 million, positioning Pyxus for more carry-over sales into fiscal 2027, but also tying up working capital.
Operations are highly concentrated: three multinational tobacco manufacturers each contributed at least 10% of annual revenue, and non-tobacco crops were less than 1% of sales. Pyxus employs about 3,300 people worldwide and faces risks from high leverage, volatile crop conditions, regulation of tobacco and nicotine products, and geopolitical and currency pressures across its many sourcing regions.
Pyxus International reported strong third quarter fiscal 2026 results, highlighted by net income of $16.9 million and adjusted EBITDA of $80.0 million, essentially matching last year’s record third quarter performance. Management reiterated that the company remains on track for one of its strongest years.
Third quarter sales and other operating revenues were $655.8 million, down from $778.3 million, mainly due to shipment timing in Africa and Europe and lower average pricing in South America tied to lower crop purchase costs. Despite lower revenue, gross margin improved to 15.2% from 15.0%, helped by larger South American crops and higher third‑party processing volumes.
For the first three quarters, sales were $1.73 billion, a 12.4% decline from $1.98 billion, while gross margin rose to 14.6% from 13.9%. Tobacco inventory increased to $959.8 million, in line with larger crops, and net debt rose by $199.4 million versus the prior year, with no outstanding borrowings on the $150.0 million ABL facility. Pyxus reaffirmed full‑year fiscal 2026 guidance, targeting net sales of $2.4–$2.6 billion and adjusted EBITDA of $215–$235 million.
Pyxus International, Inc. reported lower sales but stable quarterly profitability in its latest period. For the three months ended December 31, 2025, sales and other operating revenues fell 15.7% to $655.8 million, mainly from lower leaf tobacco volumes and prices, while gross margin ticked up to 15.2% due to favorable mix and stronger processing revenues.
Quarterly net income attributable to Pyxus was $16.9 million, down 10.6% from the prior year, but year-to-date profit dropped sharply to $0.2 million from $20.3 million as lower volumes, shipment timing and higher other expenses weighed on results. Operating cash flow was deeply negative at $(518.6) million for the nine-month period, driven by a large build in inventories and advances to suppliers tied to bigger crops.
Net debt rose to $1.16 billion, up from $960.0 million a year earlier, as the company relied more heavily on foreign seasonal lines of credit. Total tobacco inventories reached $959.8 million as of December 31, 2025, positioning Pyxus to support anticipated higher shipments later in the fiscal year but increasing working capital intensity and leverage.